The future of advanced prostate cancer treatment may involve combining ADCs with bispecific T-cell engagers. This strategy could use ADCs for a short duration to deliver a potent hit, followed by immunotherapy to achieve durable remission, potentially reducing toxicity and enabling earlier use.

Unlike checkpoint inhibitors, the bispecific antibody Pazridamig (targeting HK2 and CD3) shows promising early signals in heavily pretreated prostate cancer. It demonstrated a low rate of side effects and convenient dosing, suggesting a viable new immunotherapeutic pathway.

Unlike bladder cancer, prostate cancer has highly effective androgen-pathway inhibitors (ARPIs) that extend survival. This success has pushed chemotherapy and, by extension, ADC development to later treatment lines as clinicians prioritize other novel mechanisms of action first.

Dr. Patrick Baeuerle suggests that instead of engineering complex co-stimulatory signals into T-cell engagers, a more effective strategy is to combine them with standard-of-care treatments like chemotherapy or ADCs. This approach dramatically augments efficacy and has already prompted multiple Phase 3 trials.

The initial hope for a revolution across many immune checkpoints has faded. With most targets outside of PD-1 failing to deliver, investors and pharma have grown fatigued. This disappointment has accelerated the industry's pivot towards other modalities like ADCs and cell therapies.

A therapeutic approach called "T-cell engagers" or "BiTEs" uses engineered antibodies with two different heads. One side binds to a cancer cell, while the other binds to a nearby T-cell. This effectively brings the killer cell and the target together, leveraging the body's existing immune cells without genetic modification.

The future of advanced prostate cancer treatment is shifting towards therapies that target cell surface markers. This new era will be defined by a growing arsenal of radioligands, T-cell engaging bispecific antibodies (BiTEs), and antibody-drug conjugates (ADCs) aimed at targets like PSMA, B7-H3, and HK2.

For antibody-drug conjugates (ADCs) to make a meaningful impact in prostate cancer, the clinical development bar is exceptionally high. Merely showing activity in late-line settings is insufficient; the true measure of success is demonstrating superiority over the established chemotherapy standard, docetaxel.

While immunotherapy was a massive leap forward, Dr. Saav Solanki states the next innovation frontier is combining it with newer modalities. Antibody-drug conjugates (ADCs) and T-cell engagers are being used to recruit the immune system into the tumor microenvironment, helping patients who don't respond to current immunotherapies.